Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment.
PURPOSE: This laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.
|Lung Cancer||Biological: bevacizumab Drug: carboplatin Drug: paclitaxel Genetic: proteomic profiling Other: laboratory biomarker analysis Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||Development of a Serum Proteomic Classifier for the Prediction of Benefit From Bevacizumab in Combination With Carboplatin and Paclitaxel|
- Survival [ Time Frame: 1 day ]
|Actual Study Start Date:||March 14, 2008|
|Study Completion Date:||April 14, 2008|
|Primary Completion Date:||April 14, 2008 (Final data collection date for primary outcome measure)|
- To develop a serum proteomic classifier using matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry analysis of blood samples from patients with non-squamous cell non-small cell lung cancer to predict benefit, in terms of survival and time to progression, from treatment with bevacizumab in combination with carboplatin and paclitaxel.
- To better quantitate candidate biomarkers by using more advanced mass spectrometric technologies, including multiple-reaction monitoring and heavy-labeled peptides.
OUTLINE: Previously collected pre-treatment samples of serum or plasma are randomly selected from patients enrolled on protocol ECOG-4599 (i.e., 60 from the bevacizumab arm and 30 from the control arm). Samples are analyzed by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry to identify patterns from protein spectra that correlate with patient survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898417
|Study Chair:||David P. Carbone, MD, PhD||Vanderbilt-Ingram Cancer Center|